Welcome to our dedicated page for Aclaris Therapeutics SEC filings (Ticker: ACRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aclaris Therapeutics filings document a Nasdaq-listed clinical-stage biopharmaceutical issuer developing immuno-inflammatory disease candidates. The record includes 8-K disclosures for quarterly and annual financial results, Regulation FD presentations, clinical pipeline updates for ATI-052 and ATI-2138, and common stock sales under an amended and restated sales agreement.
Proxy materials describe board and shareholder voting matters, executive compensation, equity awards and governance procedures. The filings also identify ACRS common stock, Delaware incorporation, R&D spending, royalty revenue from Lilly and Sun Pharma license agreements and capital-structure disclosures tied to public equity financing.
Aclaris Therapeutics, Inc. received an updated ownership report showing that BML Investment Partners, L.P. beneficially owns 14,250,000 shares of its common stock, representing 11.9% of the class as of 12/31/2025.
BML reports shared power to vote and dispose of all these shares, with no sole voting or dispositive power. The filing states the securities were not acquired or held for the purpose of changing or influencing control of Aclaris.
Aclaris Therapeutics CEO and director Walker Neal reported new equity awards granted on February 2, 2026. He received 274,800 restricted stock units, each representing the right to receive one share of common stock, and an employee stock option covering 961,700 shares of common stock.
The restricted stock units vest in four equal installments on the first, second, third, and fourth anniversaries of February 2, 2026, contingent on his continued service. The stock option, with a $3.61 exercise price per share, is exercisable as it vests over the same four-year schedule, also subject to continuous service.
Aclaris Therapeutics reported new equity awards to President and COO Hugh M. Davis, who also serves as a director. On February 2, 2026, he received 96,100 restricted stock units, each representing one share of common stock, and 336,300 employee stock options with a $3.61 exercise price.
The restricted stock units vest in four equal annual installments on the first through fourth anniversaries of February 2, 2026, contingent on his continuous service. The stock options become exercisable as 25% of the shares vest in four equal annual installments on the same anniversary dates, also subject to continuous service.
Aclaris Therapeutics reported an equity compensation grant to its Chief Scientific Officer, Roland Wilhelm Kolbeck, effective February 2, 2026. He received 95,700 restricted stock units, each representing one share of common stock, and an option to purchase 334,900 shares of common stock at an exercise price of $3.61 per share.
The restricted stock units vest in four equal installments on the first through fourth anniversaries of February 2, 2026, conditioned on his continued service. The stock option becomes exercisable as to 25% of the shares on each of the first, second, third, and fourth anniversaries of February 2, 2026, also subject to continuous service.
Aclaris Therapeutics granted its Chief Medical Officer, Jesse Wayne Hall, new equity awards on February 2, 2026. The awards consist of 98,100 restricted stock units, each representing one share of common stock, and an option to purchase 343,300 shares of common stock at an exercise price of $3.61 per share.
Both the restricted stock units and the stock options vest in four equal annual installments on the first, second, third and fourth anniversaries of February 2, 2026, conditioned on Hall’s continued service with the company. Following these grants, Hall directly holds the full reported amounts of these derivative securities.
Aclaris Therapeutics’ Chief Business Officer James Loerop received new equity awards dated February 2, 2026. He was granted 97,700 restricted stock units, each representing one future share of common stock, and 341,900 employee stock options with a $3.61 exercise price.
The RSUs vest in four equal annual installments on the first through fourth anniversaries of February 2, 2026, contingent on continued service. The stock options also vest in four equal annual installments over the same schedule, becoming exercisable as service-based vesting conditions are met.
Aclaris Therapeutics Chief Financial Officer Kevin Balthaser reported new equity awards. On February 2, 2026, he received 99,100 restricted stock units, each representing one share of Aclaris common stock. These RSUs vest in four equal annual installments starting on the first anniversary of February 2, 2026, conditioned on his continued service.
He was also granted an employee stock option for 346,800 shares of common stock at an exercise price of $3.61 per share. The option becomes exercisable as 25% of the shares vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 2, 2026, also subject to continued service.
Aclaris Therapeutics Chief Business Officer James Loerop reported routine equity compensation activity. On February 3, 2026, 20,875 restricted stock units were converted into an equal number of Aclaris common shares. Each restricted stock unit represents the right to receive one share of common stock.
To cover tax withholding on this vesting, the issuer withheld 5,937 common shares at $3.47 per share, reported under transaction code F. After these transactions, Loerop directly owned 192,260 shares of common stock and 62,625 restricted stock units, which continue to vest in four equal installments on the first four anniversaries of February 3, 2025, subject to continuous service.
Aclaris Therapeutics CEO Walker Neal reported equity compensation activity involving restricted stock units and common stock. On February 3, 2026, 63,475 restricted stock units were converted into 63,475 shares of common stock at an exercise price of $0.
To cover tax withholding related to this vesting, 18,611 shares of common stock were withheld by the company at a price of $3.47 per share. After these transactions, Neal directly owned 1,543,886 shares of common stock and 190,425 restricted stock units, which vest in four equal annual installments starting on February 3, 2025, subject to continuous service.
Aclaris Therapeutics President and COO Hugh M. Davis reported an equity compensation transaction involving restricted stock units (RSUs). On February 3, 2026, 18,675 RSUs converted into 18,675 shares of Aclaris Therapeutics common stock at an exercise price of $0 per share.
After this transaction, Davis directly owned 45,425 shares of common stock and 56,025 RSUs. Each RSU represents the right to receive one share of common stock. The RSUs underlying this transaction vest in four equal annual installments on the first through fourth anniversaries of February 3, 2025, subject to his continuous service.